Evidence map›Paper›PMID 37766137›Full record

ArticleVaccines2023

Effectiveness of the Booster Dose in Protecting against COVID-19, Colombia 2022.

Jubby Marcela Gálvez, Ángela María Pinzón-Rondón, Henry Mauricio Chaparro-Solano, Hanna Valentina Tovar-Romero, Juliana Ramírez-Prieto, Sergio Andrés Ortigoza-Espitia, Ángela María Ruiz-Sternberg

Open access · goldAbstract read
In one paragraph

Article in Vaccines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Jubby Marcela GálvezGenuino Research Group, Gencell Pharma, Bogotá 111221, Colombia.
Ángela María Pinzón-RondónClinical Investigation Group, Universidad del Rosario, Carrera 24 #63C-69, Bogotá 111221, Colombia.
Henry Mauricio Chaparro-SolanoClinical Investigation Group, Universidad del Rosario, Carrera 24 #63C-69, Bogotá 111221, Colombia.
Hanna Valentina Tovar-RomeroClinical Investigation Group, Universidad del Rosario, Carrera 24 #63C-69, Bogotá 111221, Colombia.
Juliana Ramírez-PrietoClinical Investigation Group, Universidad del Rosario, Carrera 24 #63C-69, Bogotá 111221, Colombia.
Sergio Andrés Ortigoza-EspitiaClinical Investigation Group, Universidad del Rosario, Carrera 24 #63C-69, Bogotá 111221, Colombia.
Ángela María Ruiz-SternbergClinical Investigation Group, Universidad del Rosario, Carrera 24 #63C-69, Bogotá 111221, Colombia.
Universidad del Rosario · CO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vaccination has proven to be one of the most effective strategies against the COVID-19 pandemic. Several studies have evaluated and confirmed its effectiveness in different populations, particularly in reducing severe outcomes such as hospitalization and death. Some studies have investigated the effectiveness of vaccination against the infection, identifying the need for booster doses. This study aimed to explore the effectiveness of the vaccination schedule on the probability of infection in a sample of Colombian patients during the fourth wave of the COVID-19 pandemic, which was associated with the emergence and predominance of the Omicron variant. A cross-sectional study was conducted on individuals who underwent RT-PCR testing for COVID-19 detection in a dedicated laboratory in Bogotá, Colombia, between 30 December 2021 and 7 February 2022. A total of 1468 subjects was included in the study, of whom 36.6% (n = 538) had a positive PCR test for COVID-19. The comparison between fully vaccinated individuals with a booster dose and those without the booster dose revealed a 28% reduction in the odds of infection (OR = 0.719 CI 0.531-0.971). Age (OR = 1.009 CI 1.001-1.018) and low economic status (OR = 1.812 CI 1.416-2.319) were associated with an increased risk of infection. These findings suggest the need for a booster vaccination in the general population to improve the prevention rates of SARS-CoV-2 infection and mitigate severe outcomes.

Indexed as

booster doseColombiaCOVID-19effectivenessvaccination strategy

Identifiers

PMID37766137
PMCPMC10538081
OpenAlexW4386525156

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.